These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

165 related items for PubMed ID: 35498884

  • 21. Prognostic Performance of Kidney Volume Measurement for Polycystic Kidney Disease: A Comparative Study of Ellipsoid vs. Manual Segmentation.
    Shi B, Akbari P, Pourafkari M, Iliuta IA, Guiard E, Quist CF, Song X, Hillier D, Khalili K, Pei Y.
    Sci Rep; 2019 Jul 29; 9(1):10996. PubMed ID: 31358787
    [Abstract] [Full Text] [Related]

  • 22. [AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE: HOW AND WHY SHOULD WE IDENTIFY THE PATIENTS "RAPIDLY PROGRESSING" TO END-STAGE RENAL DISEASE?].
    Bodson A, Meunier P, Krzesinski JM, Jouret F.
    Rev Med Liege; 2016 Apr 29; 71(4):184-92. PubMed ID: 27295898
    [Abstract] [Full Text] [Related]

  • 23. Modelling the long-term benefits of tolvaptan therapy on renal function decline in autosomal dominant polycystic kidney disease: an exploratory analysis using the ADPKD outcomes model.
    Bennett H, McEwan P, Hamilton K, O'Reilly K.
    BMC Nephrol; 2019 Apr 23; 20(1):136. PubMed ID: 31014270
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. The association of serum angiogenic growth factors with renal structure and function in patients with adult autosomal dominant polycystic kidney disease.
    Coban M, Inci A.
    Int Urol Nephrol; 2018 Jul 23; 50(7):1293-1300. PubMed ID: 29654395
    [Abstract] [Full Text] [Related]

  • 26. Factors predicting decline in renal function and kidney volume growth in autosomal dominant polycystic kidney disease: a prospective cohort study (Japanese Polycystic Kidney Disease registry: J-PKD).
    Uchiyama K, Mochizuki T, Shimada Y, Nishio S, Kataoka H, Mitobe M, Tsuchiya K, Hanaoka K, Ubara Y, Suwabe T, Sekine A, Nutahara K, Tsuruya K, Ishimura E, Nakatani S, Sofue T, Tanaka S, Narita I, Maruyama S, Horie S, Muto S.
    Clin Exp Nephrol; 2021 Sep 23; 25(9):970-980. PubMed ID: 33928479
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Plasma metabolites and lipids associate with kidney function and kidney volume in hypertensive ADPKD patients early in the disease course.
    Kim K, Trott JF, Gao G, Chapman A, Weiss RH.
    BMC Nephrol; 2019 Feb 25; 20(1):66. PubMed ID: 30803434
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Image texture features predict renal function decline in patients with autosomal dominant polycystic kidney disease.
    Kline TL, Korfiatis P, Edwards ME, Bae KT, Yu A, Chapman AB, Mrug M, Grantham JJ, Landsittel D, Bennett WM, King BF, Harris PC, Torres VE, Erickson BJ, CRISP Investigators.
    Kidney Int; 2017 Nov 25; 92(5):1206-1216. PubMed ID: 28532709
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Magnetic resonance imaging 3T and total fibrotic volume in autosomal dominant polycystic kidney disease.
    Lai S, Mastroluca D, Letizia C, Petramala L, Perrotta AM, DiGaeta A, Ferrigno L, Ciccariello M, D'Angelo AR, Panebianco V.
    Intern Med J; 2018 Dec 25; 48(12):1505-1513. PubMed ID: 30043487
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Renal Volume in ADPKD Patient Evaluation.
    Galliani M, Vitaliano E, Chicca S, Calvaruso L, Di Lullo L, Iorio F, Tosti ME, Paone A.
    Int J Nephrol; 2020 Dec 25; 2020():9286728. PubMed ID: 32158561
    [Abstract] [Full Text] [Related]

  • 39. A model to predict disease progression in patients with autosomal dominant polycystic kidney disease (ADPKD): the ADPKD Outcomes Model.
    McEwan P, Bennett Wilton H, Ong ACM, Ørskov B, Sandford R, Scolari F, Cabrera MV, Walz G, O'Reilly K, Robinson P.
    BMC Nephrol; 2018 Feb 13; 19(1):37. PubMed ID: 29439650
    [Abstract] [Full Text] [Related]

  • 40. Effect of tolvaptan on renal involvement in patients with autosomal dominant polycystic kidney disease according to different gene mutations.
    Moriyama T, Nakayama Y, Soejima M, Yokota Y, Ota K, Ito S, Kodama G, Nakamura N, Kurokawa Y, Yano J, Ueda U, Takamiya Y, Kaida Y, Hazama T, Shibata R, Koda Y, Fukami K.
    Clin Exp Nephrol; 2021 Mar 13; 25(3):251-260. PubMed ID: 33141305
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.